公开(公告)号：US11160776B2

公开(公告)日：2021-11-02

申请号：US16812835

申请日：2020-03-09

申请人： Vireo Systems, Inc.

发明人： Mark C. Faulkner ,  Donald W. Miller ,  Grant M. Hatch

IPC分类号： A61K31/197 ,  A61K31/221 ,  A61P25/00 ,  A61P25/14

摘要： Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.

公开(公告)号：US20130131175A1

公开(公告)日：2013-05-23

申请号：US13740909

申请日：2013-01-14

申请人： Vireo Systems Inc.

发明人： Donald W. Miller ,  Jonathan L. Vennerstrom ,  Mark C. Faulkner

IPC分类号： A61K31/198

CPC分类号： A61K31/198 ,  A23K20/10 ,  A23K20/105 ,  A23K20/142 ,  A23K50/10 ,  A23L2/52 ,  A23L33/10 ,  A23L33/175 ,  A23P10/40 ,  A23V2002/00 ,  A61K9/0053 ,  A61K31/185 ,  A61K31/195 ,  A61K31/661 ,  A23V2250/306 ,  A23V2200/33 ,  A23V2200/316

摘要： The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

公开(公告)号：US10583105B2

公开(公告)日：2020-03-10

申请号：US16371779

申请日：2019-04-01

申请人： Vireo Systems, Inc.

发明人： Mark C. Faulkner ,  Donald W. Miller ,  Grant M. Hatch

IPC分类号： A61K31/197 ,  A61K31/221 ,  A61P25/00 ,  A61P25/14

摘要： Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.

公开(公告)号：US20190328693A1

公开(公告)日：2019-10-31

申请号：US16504702

申请日：2019-07-08

申请人： Vireo Systems, Inc. ,  Board of Regents of the University of Nebraska

发明人： Donald W. Miller ,  Jonathan L. Vennerstrom ,  Mark C. Faulkner

IPC分类号： A61K31/198 ,  A61K31/195 ,  A23K20/10 ,  A61K31/185 ,  A23L2/52 ,  A23L33/175 ,  A61K31/661 ,  A61K9/00 ,  A23K50/10 ,  A23K20/142 ,  A23K20/105 ,  A23L33/10

摘要： The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

公开(公告)号：US10245245B2

公开(公告)日：2019-04-02

申请号：US15133501

申请日：2016-04-20

申请人： Vireo Systems, Inc.

发明人： Mark C. Faulkner ,  Donald W. Miller ,  Grant M. Hatch

IPC分类号： A61K31/197

摘要： Compositions for neuroprotection and treatment of neurodegeneration and methods of administering same. In particular, the present invention relates to compositions and methods for preventing or reducing neurodegeneration, such as neurodegeneration caused by Huntington's disease, including administering a daily dose of a composition including an effective amount of creatine hydrochloride to a patient in need thereof. The methods of the present invention allow for lower dosages of supplementation as compared to creatine monohydrate while retaining all of the desired biological effects of creatine supplementation.

公开(公告)号：US20170049736A1

公开(公告)日：2017-02-23

申请号：US15344835

申请日：2016-11-07

申请人： Vireo Systems, Inc. ,  Board of Regents of the University of Nebraska

发明人： Donald W. Miller ,  Jonathan L. Vennerstrom ,  Mark C. Faulkner

IPC分类号： A61K31/198 ,  A23L33/10 ,  A23K50/10 ,  A23K20/10 ,  A61K9/00 ,  A23L2/52

CPC分类号： A61K31/198 ,  A23K20/10 ,  A23K20/105 ,  A23K20/142 ,  A23K50/10 ,  A23L2/52 ,  A23L33/10 ,  A23L33/175 ,  A23P10/40 ,  A23V2002/00 ,  A61K9/0053 ,  A61K31/185 ,  A61K31/195 ,  A61K31/661 ,  A23V2250/306 ,  A23V2200/33 ,  A23V2200/316

摘要： The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

摘要翻译： 本发明涉及包含肌酸盐酸盐的口服补充剂，其水溶性度是肌酸一水合物的至少15倍，其中口服补充剂由于其增强的生物利用度而促进肌肉发育和恢复的显着改善，而 与以前的肌酸形式相比，引起的副作用较少。

公开(公告)号：US09486424B2

公开(公告)日：2016-11-08

申请号：US14629532

申请日：2015-02-24

申请人： Vireo Systems, Inc. ,  Board of Regents of the University of Nebraska

发明人： Donald W. Miller ,  Jonathan L. Vennerstrom ,  Mark C. Faulkner

IPC分类号： A61K31/195 ,  A61K31/185 ,  A23L1/30 ,  A23L1/305 ,  A61K31/198 ,  A61K31/661 ,  A23L2/52 ,  A23L1/00

CPC分类号： A61K31/198 ,  A23K20/10 ,  A23K20/105 ,  A23K20/142 ,  A23K50/10 ,  A23L2/52 ,  A23L33/10 ,  A23L33/175 ,  A23P10/40 ,  A23V2002/00 ,  A61K9/0053 ,  A61K31/185 ,  A61K31/195 ,  A61K31/661 ,  A23V2250/306 ,  A23V2200/33 ,  A23V2200/316

摘要： The present invention is directed to a third generation form of creatine, specifically a creatine hydrochloride salt, that drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

公开(公告)号：US20240165067A1

公开(公告)日：2024-05-23

申请号：US18519436

申请日：2023-11-27

申请人： Vireo Systems, Inc.

发明人： Mark C. Faulkner ,  Donald W. Miller

IPC分类号： A61K31/215 ,  A61K45/06 ,  A61P31/12

CPC分类号： A61K31/215 ,  A61K45/06 ,  A61P31/12

摘要： Antiviral therapeutic compounds and compositions that may be used in methods of preventing and/or treating infection(s) caused by coronaviruses or influenza viruses.

公开(公告)号：US20210401879A1

公开(公告)日：2021-12-30

申请号：US17364105

申请日：2021-06-30

申请人： Vireo Systems, Inc.

发明人： Mark C. Faulkner ,  Deeannah Seymour

IPC分类号： A61K33/22 ,  A61K9/10 ,  A61K9/00 ,  A61K47/44

摘要： Compositions, such as aqueous solutions and non-aqueous solutions and slurries, of a weak acid are provided. The disclosed compositions may be used to treat, prevent, and/or reduce one or more symptoms associated with numerous vaginal conditions or disturbances, such as odor and itch.

公开(公告)号：US10881630B2

公开(公告)日：2021-01-05

申请号：US16504702

申请日：2019-07-08

申请人： Vireo Systems, Inc. ,  Board of Regents of the University of Nebraska

发明人： Donald W. Miller ,  Jonathan L. Vennerstrom ,  Mark C. Faulkner

IPC分类号： A61K31/198 ,  A23L33/10 ,  A23L33/175 ,  A61K31/195 ,  A61K31/661 ,  A23K20/105 ,  A23K20/142 ,  A23K50/10 ,  A23L2/52 ,  A61K31/185 ,  A23K20/10 ,  A61K9/00 ,  A23P10/40

摘要： The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.